TTRX

Turn Therapeutics Inc. (TTRX) ESG Analysis Analysis (2026)

Invetso Score: 5.4/10 — Balanced · Last Updated: 2026-08-01

Environmental

TTRX appears broadly in line with peers on direct environmental exposure, but limited disclosed metrics constrain evidence of stronger operational decarbonization versus larger industrial peers.

The absence of reported R&D intensity and gross margin data reduces visibility into resource-efficiency initiatives, leaving its environmental management harder to verify than better-disclosed peers.

No post-August 2025 filing evidence was provided on emissions, energy, or waste targets, so relative environmental positioning remains neutral rather than advantaged versus peers.

Compared with peers that publish detailed climate metrics, TTRX’s disclosure depth appears thinner, which can elevate reputational and stakeholder scrutiny even without a clear operating disadvantage.

Social

TTRX shows no provided evidence of labor, safety, or community leadership, so its social positioning cannot be assessed as stronger than peers on disclosed data.

Zero reported stock-based compensation to revenue may indicate lower employee-alignment disclosure complexity, but it does not by itself demonstrate superior workforce practices versus peers.

The lack of latest filing detail on turnover, training, or incident rates limits confidence that TTRX matches peers with more transparent human-capital reporting.

Relative to peers with broader social disclosures, TTRX appears less transparent, which can weaken stakeholder trust even absent a documented social controversy.

Governance

TTRX’s debt-to-equity ratio of 8.9 and net debt-to-EBITDA near 1.0 suggest materially higher leverage sensitivity than many peers, increasing governance scrutiny over capital discipline.

The absence of provided filing evidence on board independence, audit oversight, and shareholder rights prevents a stronger governance assessment versus peers with clearer controls.

Zero stock-based compensation to revenue may reduce dilution concerns, but it does not offset the elevated balance-sheet risk implied by the leverage metrics.

Compared with peers that maintain lower leverage and more transparent governance disclosures, TTRX appears moderately weaker on governance resilience and oversight visibility.

Overall Score

TTRX’s ESG profile is broadly middle-of-pack versus peers, with limited disclosure depth and elevated leverage being the main relative drags.

Score Driver: Elevated Leverage Combined With Thinner Governance Disclosure Versus Peers.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Turn Therapeutics Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →